NEWS & EVENTS
Company News
Press Release
For Immediate Release
June, 4, 2007
Contact: Gregg DiPietro
Leerink Swann
(617) 918-4601
Gregg.DiPietro@leerink.com
Leerink Swann appoints Jonathan P. Gertler, MD as Managing Director, Head of BioPharma Investment Banking
Boston, MA - June 4, 2007 - Healthcare investment bank Leerink Swann announced the addition of Jonathan P. Gertler, MD to its Investment Banking Group.
Dr. Gertler will join the Firm on June 13 as Managing Director, Head, BioPharma Investment Banking. He will be responsible for all investment banking activities related to the biotechnology and specialty pharmaceutical sectors.
Dr. Gertler was most recently Managing Director in Healthcare Investment Banking at Cowen and Company. Prior to that, he served as Head of Life Science Investment Banking at Adams Harkness & Hill, focusing on biotechnology and medical technology equity offerings, mergers and acquisitions and strategic advisory projects. He has been responsible for over $5 billion in aggregate deal consideration throughout his banking career.
Before joining Adams Harkness in 2001, Dr. Gertler practiced vascular surgery for over twelve years, during which time he published more than 120 peer reviewed manuscripts, abstracts and chapters on vascular surgery and biology. From 1992-2001, Dr. Gertler was one of five vascular surgeons at Massachusetts General Hospital and Associate Professor of Surgery at Harvard University. From 1988-1992, he was Chief of Vascular Surgery at SUNY-HSCB in New York. In addition to his surgical and academic responsibilities, from 1998-2001 Dr. Gertler was a venture partner for Schroder Ventures Life Science Fund, one of the world's largest dedicated life sciences and healthcare private equity funds. He was also co-founder and President of Cardiovascular Technologies, an endovascular device start-up that was successfully sold.
"Jonathan Gertler will be a tremendous addition to the Investment Banking Group ", said David Ogens, Head of Investment Banking at Leerink Swann. "His unique combination of world-class clinical, banking, and entrepreneurial expertise fits ideally with our banking platform. With Jonathan leading our BioPharma practice, we look forward to building on the outstanding momentum of our banking activities."
Dr. Gertler holds a B.A. from Wesleyan University, an M.D. from Columbia University College of Physicians and Surgeons, and an M.B.A. in Health Policy and Management from Boston University. He trained in general surgery at Yale University and in vascular surgery at Massachusetts General Hospital in Boston.
About Leerink Swann & Company
Leerink Swann is a healthcare-focused investment banking firm that provides equity research, corporate finance, asset management, and strategic advisory services for institutional, life sciences, and high-net-worth clients. For the past six years, Institutional Investor has named Leerink Swann "Best of the Boutiques" in Biotechnology, Healthcare Technology & Distribution, Medical Supplies and Devices, Pharmaceuticals/Major, and Pharmaceuticals/Specialty. Through its MEDACorp division, Leerink Swann provides biomedical-consulting services to the institutional investment community. With an internal team of experts and a dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann is a member NASD/SIPC.
"Best of the Boutiques" - Institutional Investor. Seventh consecutive year!